Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 25;2(1):e000021.
doi: 10.1136/bmjophth-2016-000021. eCollection 2017.

Diabetic retinopathy and the use of laser photocoagulation: is it cost-effective to treat early?

Hema Mistry  1 , Peter Auguste  1 , Noemi Lois  2 , Norman Waugh  1
Affiliations

Diabetic retinopathy and the use of laser photocoagulation: is it cost-effective to treat early?

Hema Mistry et al. BMJ Open Ophthalmol. .

Abstract

Background/aims: The aim of the study was to explore whether it would be cost-effective to apply panretinal photocoagulation (PRP) at the severe non-proliferative diabetic retinopathy (NPDR) (early treatment) stage, compared with waiting until high-risk proliferative diabetic retinopathy (HR-PDR) characteristics (deferred treatment) developed.

Methods: A Markov model with a 30-year time horizon was developed, in which patients presenting with moderate NPDR could progress through all stages of DR (severe NPDR>early PDR>HR-PDR>severe PDR) to severe vision loss and blindness (and to death). A National Health Service and personal social services perspective was adopted. Transition probabilities were mainly derived from the Early Treatment Diabetic Retinopathy Study. Health state utilities, costs and complications were based on information from the literature, supplemented by expert opinion. Costs and outcomes were discounted at 3.5%. Both deterministic and probabilistic sensitivity analyses were conducted.

Results: Administering PRP at the severe NPDR stage could be more effective and less costly than waiting until HR-PDR developed. Sensitivity analyses gave similar results, with early treatment continuing to dominate deferred treatment. The probabilistic sensitivity analysis suggests that at willingness-to-pay threshold of £20-£30 000 per quality-adjusted life year, the probability of early treatment being cost-effective is 60%.

Conclusion: PRP administered at the severe NPDR stage is likely to be cost-effective compared with delaying photocoagulation until HR-PDR develops. However, given the limitations of the evidence, these results need to be interpreted with caution. A trial of early versus deferred laser therapy is needed to provide better data based on modern treatments.

Keywords: cost-effectiveness; diabetic retinopathy; laser photocoagulation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
(A) Cost-effectiveness plane—usual care (usual care) versus intervention (early PRP). (B) Cost-effectiveness acceptability curve—usual care (usual care) versus intervention (early PRP). INT, intervention; PRP, panretinal photocoagulation; QALYs, quality-adjusted life years; UC, usual care.
Figure 2
Figure 2
Tornado diagram for net monetary benefit usual care (usual care) versus intervention (early PRP). NPDR, non-proliferative diabetic retinopathy; OCT, optical coherence tomography; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation; PT, post-treatment; WTP, willingness to pay.
See this image and copyright information in PMC

References

    1. Diabetes UK. Cost of diabetes. 2014. http://www.diabetes.co.uk/cost-of-diabetes.html (accessed 27 Feb 2015).
    1. Wong TY, Mwamburi M, Klein R, et al. . Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009;32:2307–13. doi:10.2337/dc09-0615 - DOI - PMC - PubMed
    1. Younis N, Broadbent DM, Harding SP, et al. . Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabet Med 2003;20:758–65. doi:10.1046/j.1464-5491.2003.01035.x - DOI - PubMed
    1. Yau JW, Rogers SL, Kawasaki R, et al. . Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–64. doi:10.2337/dc11-1909 - DOI - PMC - PubMed
    1. Royle P, Mistry H, Auguste P, et al. . Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Health Technol Assess 2015;19:1–248. doi:10.3310/hta19510 - DOI - PMC - PubMed